Fatalities in Novartis CAR-T trials spark debate on risk tolerance for autoimmune therapies

Three patient deaths in Novartis' CAR-T trials for autoimmune diseases have prompted researchers to reconsider the safety thresholds for this emerging treatment. While many see CAR-T as a potential breakthrough for autoimmune conditions, the fatalities highlight the need to balance efficacy with acceptable risks. The events underscore the challenges in translating cancer cell therapies to non-oncology indications.

The recent deaths in Novartis’ CAR-T studies for autoimmune diseases have intensified scrutiny of how these cell-based therapies are being tested beyond oncology. CAR-T, which reprograms a patient’s immune cells, has shown promise in hard-to-treat cancers, but its application to conditions like lupus or multiple sclerosis is still experimental. These fatalities force a closer look at patient selection, dosing, and monitoring protocols. Researchers are now weighing whether the potential for long-term remission justifies the immediate risks, especially in diseases that are not immediately life-threatening. The events also highlight the steep learning curve when adapting a cancer treatment to a different patient population with distinct immune profiles and organ vulnerabilities.